CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Areas of severe narrowing, stenosis, detectable by angiography, and to a lesser extent "stress testing" have long been the focus of human diagnostic techniques for cardiovascular disease, in general. However, these methods focus on detecting only severe narrowing, not the underlying atherosclerotic disease. As demonstrated by human clinical studies, most severe events occur in locations with heavy plaque, yet little or no lumen narrowing present before debilitating events suddenly occur. Plaque rupture can lead to artery lumen occlusion within seconds to minutes, potentially permanent disability, and sometimes sudden death. Plaques that have ruptured are known as complicated lesions. The extracellular matrix of the lesion breaks, usually at the shoulder of the fibrous cap that separates the lesion from the arterial lumen, where the exposed thrombogenic components of the plaque, mainly collagen, will trigger thrombus formation. The thrombus then travels downstream to other blood vessels, where the blood clot may partially or completely block blood flow. If the blood flow is completely blocked, cell death occurs due to the lack of oxygen supply to nearby cells, resulting in necrosis. The narrowing or obstruction of blood flow can occur in any artery within the body. Obstruction of arteries supplying the heart muscle results in a heart attack, while the obstruction of arteries supplying the brain results in an ischaemic stroke.
== Non-human infections == Streptococcus agalactiae was historically studied as a disease of cattle that harmed milk production, leading to its name "agalactiae" which means "absence of milk". Strains of bovine and human bacteria are generally interchangeable, with evidence of transmission from animals to humans and vice versa.
=== Saddiction and hiatus (2024–present) === At the beginning of February 2024, Hangman's Chair returned to perform at Le Mondial du Tatouage – Tattoo Planetarium, which brought together 500 tattoo artists from around the world, at Paris' Grande halle de la Villette. In October 2024, the band released the single "2 am Thoughts" and its music video, taken from the upcoming seventh album, Saddiction. "2 am Thoughts" features a guest appearance from Raven van Dorst of Dool. The music video follows Nackphouminh, the original singer of Hangman's Chair, through a day in his life, three years after he adopted a healthier lifestyle combining sport and spiritual exploration. He is the author of the video's closing line. The band went on a European tour with Dool in October 2024. They released the single "Kowloon Lights" in November. Saddiction was released on 14 February 2025 through Nuclear Blast Records, with the group's lineup remaining unchanged: Chanut, Thépegnier, Hanvic, and Toufouti. A Loner and Saddiction would be part of a new trilogy. The album entered at number 13 on the French SNEP–SCPP Rock and Metal Chart compiled by the OCC. Mathieu David of Rolling Stone France wrote that Hangman's Chair "continues to weave their simultaneously heavy and hovering ambiences amidst mysterious urban landscapes". He added that while A Loner "hovered at 10,000 feet in an ethereal cloud, Saddiction brings back the riffs, not without reminding the harshest ambiences of Banlieue Triste". Other singles followed: "In Disguise", "Healed?", and "The Worst is Yet to Come".
A number of Singaporean writers such as Tan Swie Hian and Kuo Pao Kun have contributed work in more than one language. Singapore has a diverse music culture that ranges from pop and rock, to folk and classical. Western classical music plays a significant role in the cultural life in Singapore, with the Singapore Symphony Orchestra (SSO) instituted in 1979. Other notable western orchestras in Singapore include Singapore National Youth Orchestra and the community-based Braddell Heights Symphony Orchestra. Many orchestras and ensembles are also found in secondary schools and junior colleges. Various communities have their own distinct ethnic musical traditions: Chinese, Malays, Indians, and Eurasians. With their traditional forms of music and various modern musical styles, the fusion of different forms account for the musical diversity in the country. The nation's lively urban musical scene has made it a centre for international performances and festivals in the region. Some of Singapore's best known pop singers include Stefanie Sun, JJ Lin, Liang Wern Fook, Taufik Batisah and Dick Lee, who is famous for composing National Day theme songs, including Home.
Sources: en.wikipedia.org
Muscle glycogen storage diseases (Muscle GSDs) and other inborn errors of carbohydrate metabolism that affect muscle—defect in sugar (carbohydrate) metabolism. The deficiency occurs in the cytosol of the muscle cell. Fatty acid metabolism disorder (fatty acid oxidation disorder, FAOD)—defect in fat (lipid) metabolism, anywhere along the pathway, starting from entering the muscle cell and ending at converting fatty acids into acetyl-CoA within the mitochondrion. The deficiency occurs in the cell membrane, cytosol, mitochondrial membrane, or within the mitochondrion of the muscle cell. Nucleotide metabolism disorder—defect in purine nucleotide cycle enzyme (such as AMP deaminase deficiency). Purine nucleotide metabolism is a part of protein catabolism, and the purine nucleotide cycle occurs within the cytosol of the muscle cell. Mitochondrial myopathy—defect in mitochondrial enzymes or transport proteins for oxidative phosphorylation (including citric acid cycle and electron transport chain), excluding those for fatty acid oxidation. Occurs in the mitochondrial membrane or within the mitochondrion of the muscle cell.
=== Casting === Upon the pilot order announcement, Bates was cast to star. Skye P. Marshall, Jason Ritter, David Del Rio, and Leah Lewis joined the main cast upon the series order announcement. On February 8, 2024, Beau Bridges was cast in a recurring capacity. On April 1, 2024, Yael Grobglas joined the cast in a recurring role. In August 2024, Andrea Londo and Piper Curda were cast in recurring capacities. On September 8, 2024, Bates said that Matlock was to be her final role before retirement. On October 9, 2024, she walked it back, saying that "I think that they got a bit confused." On August 1, 2025, Justina Machado joined the cast in a recurring role for the second season. On October 9, 2025, it was reported that Del Rio had been fired due to a sexual assault allegation involving Lewis. On December 11, 2025, Henry Haber and Sarah Wright Olsen were cast in recurring capacities for the second season.
== Causes == Although its etiology is not fully understood yet, numerous factors have been suspected to be contributing towards the occurrence of DSLD in horses. It can be genetic predisposition, conformation-related problems, or the environmental causes, like improper nutrition or too much physical stress. It is highly desirable that such factors are thoroughly examined in order to achieve prevention and management. DSLD was once considered a condition of the legs only, as one of the most visible signs is when the fetlocks, particularly on the hind legs, collapse into a "coon-footed" position. However, microscopic examination in necropsy has shown DSLD horses can not only be affected in the tendons and ligaments of all legs and the patella, but can have affected tissues in the nuchal ligament, eyes, aorta, skin and fascia, lungs and other organs, as well as ligaments and tendons throughout the body. Because of its systemic nature, and because connective tissue is present everywhere in a biological entity, the entire body becomes affected in multiple ways as the disease progresses. Some horses have shown an iron overload in the liver as well. Ongoing research is working on the biochemical aspects of the disease and has found a problem in the transfer growth factor and decorin. It is strongly believed to be passed genetically, and those aspects are being studied in the search for a DNA marker.
Sources: en.wikipedia.org
The limitations of 3D bioprinting are associated with physiologically irrelevant morphology and unsuccessful histological evaluation methods. 3D bioprinting contributes to significant advances in the medical field of tissue engineering by allowing for research to be done on innovative materials called biomaterials. Some of the most notable bioengineered substances are usually stronger than the average bodily materials, including soft tissue and bone. These constituents can act as future substitutes, even improvements, for the original body materials. In addition, the Defense Threat Reduction Agency aims to print mini organs such as hearts, livers, and lungs as the potential to test new drugs more accurately and perhaps eliminate the need for testing in animals. For bioprinted food like meat see #Food and drink.
== Legacy == David Lipman, director of the National Center for Biotechnology Information, has called Dayhoff the "mother and father of bioinformatics". Her seminal contributions as the mother of the science of bioinformatics, now routinely used as part of the process for naming bacteria, were acknowledged with a bacterium being named after her in 2020, Enemella dayhoffiae. Dayhoff was inducted into the Maryland Women's Hall of Fame in March 2026.
Potash is primarily a mixture of potassium salts because plants have little or no sodium content, and the rest of a plant's major mineral content consists of calcium salts of relatively low solubility in water. While potash has been used since ancient times, its composition was not understood. Georg Ernst Stahl obtained experimental evidence that led him to suggest the fundamental difference of sodium and potassium salts in 1702, and Henri Louis Duhamel du Monceau was able to prove this difference in 1736. The exact chemical composition of potassium and sodium compounds, and the status as chemical element of potassium and sodium, was not known then, and thus Antoine Lavoisier did not include the alkali in his list of chemical elements in 1789. For a long time the only significant applications for potash were the production of glass, bleach, soap and gunpowder as potassium nitrate. Potassium soaps from animal fats and vegetable oils were especially prized because they tend to be more water-soluble and of softer texture, and are therefore known as soft soaps. The discovery by Justus Liebig in 1840 that potassium is a necessary element for plants and that most types of soil lack potassium caused a steep rise in demand for potassium salts. Wood-ash from fir trees was initially used as a potassium salt source for fertilizer, but, with the discovery in 1868 of mineral deposits containing potassium chloride near Staßfurt, Germany, the production of potassium-containing fertilizers began at an industrial scale.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.